

RECENTED 16 2003

CH CENTER 1600/290

In re Application of: Gennady MERKULOV et al. Art Unit: 1646

Serial No.: 09/768,781

Examiner: N. Basi

Filed: January 25, 2001

Atty. Docket: CL001057CIP

For: Isolated Human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof

Statement Regarding Duty to Disclose Information Material To Patentability Under 37 CFR 1.56 (a) and (b)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

The undersigned states that each item listed on the attached PTO Form SB/08A was first cited in a communication from a Foreign Patent Office in the above application's foreign counterpart or not known to the Undersigned for more than three months prior to the filing of this Information Disclosure Statement.

No fee is due for this IDS Submission. However, the Office is authorized to charge any other necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

Lin Sun-Hoffman, Ph.D., Reg No. 47,983

Date: July 15, 2003

Celera Genomics Corporation 45 West Gude Drive, C2-4#21 Rockville, MD 20850

Tel: 240-453-3628 Fax: 240-453-3084

PTO/SB/06A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known			
Application Number	09/768,781		
Filing Date	January 25, 2001		
First Named Inventor	Gennady MERKULOV et al.		
Art Unit	1646		
Examiner Name	N. BASI		
Attorney Docket Number	CL001057CIP		

	U.S. PATENT DOCUMENTS					
Examiner Initials		Document Number Number - Kind Code ² (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-		A A A CONTRACTOR CONTRACTOR OF THE CONTRACTOR OF	Figure - 1 strate at a vive fact (155 mm at) - 2 philosophic visite transportation recommended	
		US-		and the second s		
		US-	en de de marcher (de la	. I, with minimum property and the special section of the section	and a finish a, who we have writing a symbols and balance of sections of sections and also the section of	
		US-			RECEIVED	
		US-		en en 17 New York of the fact	DECEIVE	
		US-	on an analysis of the second	الما موجود الموافقة ا	nL"	
		US-			JUL 1 6 2003	
		us-		n a de la	JUL 1 0 200	
		US-	innament distance (n. 1.	13 - 15 m F. Mars S. Law was Existence by Complement parlamentary was made by Arthur	and the state of t	
	L,	US-		4 Sec. 1 11 11 11 11 11 11 11 11 11 11 11 11	TECH CENTER 1600	
		US-	· · · · · · · · · · · · · · · · · · ·		TECH UEINIETT	
mi, - in i.		US-		, , , , , , , , , , , , , , , , , , , ,		
. 4		US-				
		US-				
		US-	were a process assessment to the contract of t	and the second s	and the state of t	
		US-				
		US-		gy a market to the equivalent to the entering the entering of		
. . .		US-				
		us-				
	l	US-				

FOREIGN PATENT DOCUMENTS						
Examiner Cite	Cite	Foreign Patent Document	Publication Date	Applicant of Cited Desument Where Reli	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No. 1	Country Code 3 - Number 4 - Kind Code 5 (if Innown)			Applicant of Cited Document	or Relevant Figures Appear
		WO 01 55343 A	08/02/2001	Human Genome Sciences		
		WO 01 90304 A	11/29/2001	Human Genome Sciences		<u> </u>
. ,		en describentes har marines mens l'accessant accessant par la recomp () e en per ex per en en ex-				
				and the second s		
, ,						
<i> </i>		where we start the start and the section of the sec				
		and the second control of the second		. I di in la companya departmenta companya companya di		

Examiner		Date	
Signature	l l	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Sheet

Examiner

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
2 of 2

Complete if Known				
Application Number	09/768,781			
Filing Date	January 25, 2001			
First Named Inventor	Gennady MERKULOV et al.			
Group Art Unit	1646			
Examiner Name	N. BASI			
Attorney Docket Number	CL001057CIP			

Examiner nitials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher_city and/or country where published.	T 2	
		Database FASTA 'Online! Database accession No. Z73417. XP002235483.		
		Database BLASTP 'Online! Database accession No. P51811. XP002235485.		
		Database FASTA 'Online! Database accession No. Q9QXY7. XP002235486.		
THE SHARES AND ASSESSED.		Ho Mengfatt et al. "Isolation of the Gene for McLeod Syndrome that Encodes a Novel Membrane Transport Protein." Cell. Vol. 77, No. 6, 1994, Pages 869-880. XP001146547.		
		Collec Emmanuel et al. "Structure and Expression of the Mouse Homologue of the XK Gene." Immunogenetics. Vol. 50, No. 1-2, October 1999. Pages 16-21. XP002235481. Lee S et al. "The Kell Blood Group System: Kell and XK Membrane Proteins." Seminars in Hematology. United States APR 2000. Vol. 37, No. 2, April 2000. Pages 113-121.		
		XP009008315. International Search report dated April 24, 2003.		
in a gradual state of a		International ocalest report dated 74pm 24, 2003.	1	ED
		REC	6	2003
		RECT JUL TECH CE	NTE	1600
		JEOU o-		

Date

Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.